Avastin/Lucentis Update 47: Should the UK’s NICE Consider Adding Avastin to It’s Approved Drugs?
In a blog, appearing on the BMJ (British Medical Journal) Group Blogs, James Raftery, a health economist with several decades' experience with the National Health Service (NHS) and a professor of health technology assessment at Southampton University, regularly writes about NICE (the UK’s National Institute for Health and Clinical Excellence). He is a keen "NICE-watcher," and has provided economic input to technical assessment reports for NICE.
In this blog entry, he discusses the case to be made for including Avastin in the approved drug registry for treating AMD and DMO (or DME, as we know it).